Values as of: 2024-04-15
COMMON STOCK | Biotechnology | OTC Pink
Last Closing
USD 126.05Change
+3.05 (+2.48)%Market Cap
USD 13.38BVolume
100.00Analyst Target
N/AVerdict
Verdict
UCB SA is a biopharmaceutical company engaged in discovery & development of medicines in the fields of oncology, central nervous system disorders. The products include Cimzia, Vimpat, Neupro, Keppra, and among others.
Company Website : http://www.ucb.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| NONOF | Novo Nordisk A/S |
N/A |
USD 564.56B |
| CMXHF | CSL Limited |
N/A |
USD 89.03B |
| CSLLY | CSL Ltd |
N/A |
USD 84.45B |
| UCBJY | UCB SA ADR |
N/A |
USD 24.49B |
| ARGNF | argenx SE |
N/A |
USD 22.81B |
| GNMSF | Genmab A/S |
N/A |
USD 18.12B |
| WXIBF | WuXi Biologics |
N/A |
USD 7.17B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 7.17B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 6.76B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 5.92B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange (OTC Pink) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 44.72% | 80% | B- | 87% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 44.72% | 80% | B- | 87% | B+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 53.72% | 89% | A- | 89% | A- | ||
| Dividend Return | 1.72% | 69% | C- | 21% | F | ||
| Total Return | 55.44% | 89% | A- | 89% | A- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 44.40% | 86% | B+ | 80% | B- | ||
| Dividend Return | 7.80% | 64% | D | 26% | F | ||
| Total Return | 52.20% | 86% | B+ | 79% | B- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 6.10% | 52% | F | 50% | F | ||
| Dividend Return | 7.58% | 53% | F | 48% | F | ||
| Total Return | 1.49% | 79% | B- | 32% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 26.48% | 90% | A- | 77% | C+ | ||
| Risk Adjusted Return | 28.63% | 78% | C+ | 65% | D | ||
| Market Capitalization | 13.38B | 99% | N/A | 95% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
